Cannabinoids and Gut Microbiome Research — J.P. Hemp Company



Health Topics — Gut Health

Cannabinoids and Gut Microbiome Research

The body's cannabinoid system and its resident gut bacteria influence each other — what the research has actually examined, what it has found, and why this is one of the most overstated areas in contemporary health science.

Standard Research · Tier 2
Last Reviewed: August 2026
~1900 words
Primarily Preclinical — Observational Human Data Where Noted
Archival gut tissue plate — intestinal wall cross-section with ECS receptor expression in 19th-century engraving style
Gut microbiome and ECS reference plate

The gut microbiome and the endocannabinoid system influence each other in ways that are genuinely documented and genuinely interesting. They are also two of the most overclaimed subjects in contemporary health and wellness coverage — which makes reading the research carefully more important, and more difficult, than usual.

Primarily Preclinical — Observational Human Data Where Noted

The Bidirectional Relationship — What Is Actually Established

The gut-brain axis article in this pillar introduced the ECS-microbiome relationship as bidirectional — the ECS shapes the microbial environment, and microbial metabolites in turn influence the ECS. Both directions of that relationship have documented mechanistic support. Neither direction has been translated into a clinical intervention with demonstrated outcomes in humans.

The ECS influences the microbiome primarily through its regulation of gut physiology — motility, secretion, mucus production, and gut barrier integrity. CB1 activation slows gut transit, alters the rate of fluid secretion into the gut lumen, and modulates the thickness and composition of the mucus layer that lines the intestinal wall. These changes alter the physical and chemical environment in which gut bacteria live, and different bacterial communities thrive under different gut conditions. An ECS that maintains normal gut transit supports a microbial ecosystem different from one in which CB1 is chronically overactivated and transit is slow. The specific bacterial taxa most sensitive to ECS-mediated gut physiology changes have been characterized in animal studies; the human picture is less defined.

Microbial metabolites influence the ECS through at least two routes. Short-chain fatty acids — butyrate, propionate, and acetate, produced when commensal bacteria ferment dietary fiber — can activate CB1 and CB2 receptors directly and can stimulate enteroendocrine cells to produce endocannabinoids locally. Certain bacterial lipids structurally resemble endocannabinoid precursors and may influence endocannabinoid synthesis. The result is that the composition of the gut microbiome — which determines what metabolites are produced — partially shapes the tone of the local endocannabinoid system, which in turn shapes the gut environment, which shapes the microbiome. The feedback loop is real, slow-moving, and not well characterized in humans at the level of specific taxa and specific ECS effects.

What Dysbiosis Does to Endocannabinoid Tone

Dysbiosis — a disrupted or altered gut microbiome composition — is associated with changes in endocannabinoid tone in animal studies. The most studied pattern involves high-fat diet-induced obesity, where gut microbiome disruption correlates with elevated peripheral endocannabinoid levels (particularly 2-AG) and increased intestinal permeability — the so-called leaky gut phenomenon in which the gut barrier becomes more permeable to bacterial products and inflammatory signals.

Dysbiosis, Endocannabinoid Tone, and Gut Barrier — The Preclinical Picture
Observation
Evidence Basis and Significance
Reduced Akkermansia muciniphila in obese mice
Akkermansia muciniphila is a bacterium associated with gut barrier integrity and metabolic health. Its abundance is reduced in diet-induced obese mice and in some human obesity studies. CB1 activation is associated with reduced mucus layer thickness — the niche Akkermansia occupies — providing a plausible mechanistic link between elevated CB1 tone and reduced Akkermansia abundance. Direction of causality not established.
LPS translocation and CB1 tone
Lipopolysaccharide (LPS) — a component of gram-negative bacterial cell walls — can cross a compromised gut barrier and trigger systemic low-grade inflammation. High-fat diet dysbiosis is associated with both increased gut permeability and elevated endocannabinoid tone, and CB1 overactivation in gut epithelial cells has been shown to reduce tight junction protein expression, contributing to permeability. This is a preclinical finding — the extent to which it operates in humans is not established.
SCFA production and local endocannabinoid synthesis
Butyrate — the primary SCFA fuel source for colon epithelial cells — stimulates local endocannabinoid production in gut tissue in animal models. Microbial communities that produce more butyrate (associated with fiber-rich diets and diverse microbiomes) may support higher local endocannabinoid tone in the colon. Whether this relationship holds in humans and at what magnitude has not been adequately studied.
Probiotic supplementation and ECS markers
Some animal studies have shown that probiotic supplementation — introducing specific beneficial bacteria — alters gut endocannabinoid levels and reduces intestinal permeability in ways partially dependent on CB1 and CB2 signaling. These are proof-of-concept findings that the relationship exists, not clinical evidence that probiotic or cannabinoid interventions produce meaningful microbiome or ECS changes in humans.

Cannabinoid Use and Microbiome Composition — The Observational Data

Several human observational studies have compared gut microbiome composition between cannabis users and non-users. The findings are consistent enough to warrant attention and preliminary enough to resist strong interpretation.

Observational Research — Cannabis Users vs. Non-Users

General Pattern Across Studies: Regular cannabis users show measurable differences in gut microbiome composition compared to non-users across multiple studies. The differences are not random — certain bacterial taxa appear consistently elevated or reduced in users. Bacteroidetes-to-Firmicutes ratio differences, Prevotella abundance, and Akkermansia levels have been reported as differing between groups in some studies.

The Confounding Problem: Cannabis users differ from non-users in multiple ways beyond cannabinoid exposure — dietary patterns (cannabis use is associated with increased caloric intake, particularly processed foods), alcohol and tobacco co-use, stress levels, sleep patterns, socioeconomic factors, and more. The gut microbiome is exquisitely sensitive to all of these variables. No observational study of cannabis users can isolate the effect of cannabinoids on the microbiome from the effect of the lifestyle and dietary patterns correlated with cannabis use. Observed microbiome differences between users and non-users cannot be attributed to cannabinoids specifically.

What the Data Cannot Establish: These studies cannot determine whether cannabinoids cause microbiome differences, whether microbiome differences influence cannabis use patterns, whether a third variable drives both, or whether the observed differences have any meaningful health consequences in either direction.

CBG Specifically: No observational study has examined CBG users specifically. The cannabis-user microbiome literature is dominated by THC-containing cannabis. Extrapolating those findings to isolated non-psychoactive cannabinoids is not supported.

On the "Gut Health" Marketing Context

Gut microbiome science has become one of the most heavily marketed domains in consumer health. Probiotic, prebiotic, fermented food, and now cannabinoid products are routinely marketed with microbiome claims that substantially exceed the evidence. The fact that the ECS and the microbiome influence each other — which is genuinely documented — does not establish that any specific product or intervention improves microbiome health in clinically meaningful ways. That claim requires randomized controlled trial evidence with clinically relevant endpoints. That evidence does not currently exist for cannabinoids in this domain.

This archive does not make microbiome health claims for any product. This article describes what the research has examined and what it has found.

CBG's Antibacterial Activity — A Separate Research Thread

CBG has documented antibacterial activity — most prominently against methicillin-resistant Staphylococcus aureus (MRSA) — that is discussed in the Gut Health pillar. This is worth distinguishing from the microbiome-ECS relationship discussed above. CBG's antibacterial properties raise a separate and unresolved question: does CBG's activity against certain bacterial strains affect commensal gut bacteria alongside pathogenic ones?

Broad-spectrum antibiotics are well documented to disrupt the gut microbiome. Whether CBG's more targeted antibacterial activity — which operates through different mechanisms than traditional antibiotics — affects commensal bacteria in the gut is unknown. No studies have examined CBG's effects on the human or animal gut microbiome directly, including whether its antibacterial properties alter microbial community composition. This is a genuine research gap, not a settled finding in either direction.

The Honest Evidence Summary

The ECS and the gut microbiome influence each other bidirectionally through gut physiology, endocannabinoid synthesis, and microbial metabolite production. This relationship is mechanistically documented in animal studies and partially supported by observational human data on cannabis users. The specific bacterial taxa most affected, the magnitude of the effects in humans, and the health consequences of those effects are not established.

No cannabinoid intervention — including CBG or CBD — has been shown in a controlled human study to improve gut microbiome composition or produce clinically meaningful microbiome-mediated health outcomes. CBG's antibacterial activity raises questions about microbiome effects that have not been studied. The biology is genuinely interesting. The clinical translation is not yet there.

References

  1. Cani, P.D., Plovier, H., Van Hul, M., et al. (2016). Endocannabinoids — at the crossroads between the gut microbiota and host metabolism. Nature Reviews Endocrinology, 12(3), 133–143.
  2. Cryan, J.F., O'Riordan, K.J., Cowan, C.S.M., et al. (2019). The microbiota-gut-brain axis. Physiological Reviews, 99(4), 1877–2013.
  3. Cluny, N.L., Keenan, C.M., Reimer, R.A., et al. (2015). Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with Δ9-tetrahydrocannabinol. PLOS ONE, 10(12), e0144270.
  4. Muccioli, G.G., Naslain, D., Bäckhed, F., et al. (2010). The endocannabinoid system links gut microbiota to adipogenesis. Molecular Systems Biology, 6, 392.
  5. Panee, J., Gerschenson, M., & Chang, L. (2018). Associations between microbiota, mitochondrial function, and cognition in chronic marijuana users. Journal of Neuroimmune Pharmacology, 13(1), 113–122.
  6. Russo, E.B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
  7. Zhu, C., Sawrey-Kubicek, L., Bardagjy, A.S., et al. (2020). Whole egg consumption increases plasma choline and betaine, and supports favorable gut microbiome outcomes compared with egg white consumption in overweight adults. Journal of Nutrition, 150(10), 2749–2757.
Health Topics — Gut Health — Standard Research · Tier 2
Last Reviewed: August 2026

These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.